Thursday, June 29, 2023 4:44:30 AM
So, what is next for VSTM in terms of catalysts and results? Any upcoming data points? Is it now free from funding worries and free to focus on producing results? Tartia, your input would be appreciated.
Recent VSTM News
- Verastem Oncology to Present at Jefferies Healthcare Conference • Business Wire • 05/27/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:23:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:18:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:12:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 12:15:11 PM
- Verastem Oncology Appoints Michael P. Bailey to its Board of Directors • Business Wire • 05/26/2026 11:30:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:21:41 PM
- Verastem Oncology to Present at Upcoming Investor Conferences • Business Wire • 05/12/2026 11:30:00 AM
- On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer • Business Wire • 05/08/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:11:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:07:25 PM
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:01:09 PM
- Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 04/30/2026 11:30:00 AM
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/23/2026 11:30:00 AM
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers • Business Wire • 04/10/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:14:51 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 09:20:14 PM
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 • Business Wire • 03/17/2026 10:03:00 PM
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers • Business Wire • 03/17/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:15:33 PM
